VBI Vaccines — Corporate Update (September 2021)
11 slides from VBI Vaccines's corporate update, Sep 29, 2021
Slide 1: VBI Conference Call: New Preclinical Data and Initiation of VBI-2905 Clinical Study
YY WY, V B mw = VACCINES 7IM\s CZ \\ ACTIVATING THE POWER WITHIN VBI Conference Call New Preclinical Data and Initiation of VBI-2905 Clinical Study Targeting Broadened Immunity Against COVID-19 and Variants of Concern 8:30AM ET September 29, 2021
Slide 2: Forward-Looking Statements
my i iy om Forward-Looking Statements Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking
Slide 3: VBI's Coronavirus Pipeline is Being Developed to Increase Breadth of Protection Against COVID-19
VBI's Coronavirus Pipeline is Being Developed with the Objective to Increase Breadth of Protection Against COVID-19 Schematic Construct Design VBI-2901 Trivalent Pan-Coronavirus Ancestral COVID-19, MERS, SARS spike antigens VBI-2902 Monovalent COVID-19 > — 4 Vil 2 - eviP md (@w, ft» Ancestral COVID-
Slide 4: In Phase 1a Clinical Study, VBI-2902 Induced Neutralizing Titers Comparable to Approved mRNA Vaccines
In Phase 1a Clinical Study, VBI-2902 Induced Neutralizing Titers Comparable to Approved mRNA Vaccines After two doses of 5ug, VBI-2902a elicited neutralizing antibody (nAb) responses 4.3X higher than a panel of convalescent sera, without the use of a next-generation adjuvant Neutralizing Activity Co
Slide 5: Replication of SARS-CoV-2 Contributes to Increasing Mutations and Variants of Concern
The Replication of SARS-CoV-2 on a Global Scale Contributes to the Increasing Number of Mutations and Variants of Concern E484K Is an escape mutations and is credited with Beta's vaccine escape ~ DBI4G is associated with increased "| transmission rates and is now fixed in all globally circulating Va
Slide 6: New Preclinical Data Demonstrate Immunogenicity of VBI-2905 as 2-Dose Regimen and 1-Dose Booster
Geometric Mean Titers (GMT) New Preclinical Data Demonstrate Immunogenicity of VBI-2905 as Both a 2-Dose Regimen and 1-Dose Booster Mice primed with VBI-2902, targeting ancestral SARS-CoV-2, followed by Beta-targeting VBI- 2905 (heterologous boost) resulted in robust and balanced immunity across var
Slide 7: Hamster Challenge Data Demonstrate Ability of VBI-2905 to Protect Against Beta Variant
Hamster Challenge Data Demonstrate Ability of VBI-2905 to Protect Against Infection from Beta Variant of COVID-19 As observed in previous hamster challenge studies of VBI-2902a, neutralizing antibody titers against the Beta variant correlated with protection of disease (weight loss) after challenge
Slide 8: VBI-2901 Induced Robust Antibody and Neutralizing Titers Against Extended Panel of Variants
VBI-2901 Induced Robust Antibody and Neutralizing Titers Against an Extended Panel of Variants VBI-2901 induced higher and more consistent immunogenicity against Beta, Delta, Kappa, and Lambda variants, with evidence for broadening immunity rather than just boosting cross-reactive antibodies Neutral
Slide 9: VBI-2905 Phase 1b Study Design & Objectives
VBI-2905 Phase 1b Study Design & Objectives Study supported by CEPI collaboration Randomized, observer-blind, placebo-controlled Phase Ib study in ~80 healthy adults age 18-54 years Key objectives of the study are to assess the safety, tolerability, and immunogenicity of VBI-2905 across two regimens
Slide 10: Summary & Next Steps
Summary & Next Steps * In addition to developing vaccines to support parts of the world that have not received adequate protection due to limited supply of the ancestral strain vaccines, VBI is working to broaden immunity against COVID-19 and betacoronaviruses through two main approaches: + Heterolo
Slide 11: Zam
WW Zam